Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PLSE
SELLPulse Biosciences, Inc. · Healthcare · United States · $2.1B · Avg Vol: $11M/d
COMPANY DESCRIPTION
Pulse Biosciences is a novel medical technology company pioneering the development of its proprietary Nano-Pulse Stimulation (NPS) technology for cellular tissue clearance. The company's CellFX system delivers nanosecond electrical pulses to non-thermally clear targeted cells while sparing surrounding non-cellular tissue. Its competitive moat is anchored by a robust intellectual property portfolio and a unique, high-margin consumable business model in dermatology and other surgical applications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7M | 0 | 0 | 0.3M | -20.6% | 0.8M | 2.6M | 8.9M | 403.3% |
| EPS | -1.69 | -0.85 | -0.92 | -1.08 | — | -1.11 | -1.07 | -1.09 | — |
| Shares | 37.9M | 56.1M | 65.9M | 67.8M | +79.2% | 69.2M | — | — | — |
| Debt | 76.0M | 9.1M | 8.9M | 7.5M | -53.7% | 7.2M | — | — | — |
| Equity | -2.2M | 44.4M | 114.9M | 80.7M | 34.8% | — | — | — | — |
| Op CF | -47.0M | -33.0M | -36.3M | -54.1M | — | -55.2M | — | — | — |
| Inv CF | -0.4M | -0.1M | -0.1M | -0.3M | — | — | — | — | — |
| Fin CF | 79.9M | 16.4M | 110.1M | 17.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLSE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PLSE | Pulse Biosciences, Inc.(you) | $2.1B | 22 | SELL |
| KMTS | Kestra Medical Technologies, Ltd. | $1.2B | 21 | SELL |
| WRBY | Warby Parker Inc. | $3.0B | 41 | HOLD |
| ATRC | AtriCure, Inc. | $1.8B | 48 | HOLD |
| MMED | MiniMed Group, Inc. | $4.7B | 37 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
| RGEN | Repligen Corporation | $7.4B | 40 | HOLD |
| STAA | STAAR Surgical Company | $1.2B | 56 | HOLD |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 75 | BUY |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%